Nuclear Medicine

PET/CT Radiopharmaceutical Drugs

01. 18F‑FDG

Maps glucose metabolism to help find and monitor cancers; also used in heart viability and certain brain conditions for functional assessment.

02. 18F‑PSMA

Targets PSMA to detect prostate cancer at staging and recurrence, delivering high‑contrast pelvic imaging.

03. 18F‑Flutemetamol (FMM)

A radioactive diagnostic agent indicated for PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment.

About

HKCL specializes in developing and producing high-quality Positron Emission Tomography (PET) radiopharmaceuticals, such as Fluorodeoxyglucose (18F-FDG), Prostate-Specific Membrane Antigen (18F-PSMA), and 18F-Flutemetamol (18F-FMM). HKCL also expedites products and solutions in Dosimetry, Calibration Sources and Radiation Protection.